Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment

Abstract

Synthetic nanoparticles with surface bioconjugation are promising platforms for targeted therapy, but their simple biological functionalization is still a challenging task against the complex intercellular environment. Once synthetic nanoparticles enter the body, they are phagocytosed by immune cells by the immune system. Recently, the cell membrane camouflage strategy has emerged as a novel therapeutic tactic to overcome these issues by utilizing the fundamental properties of natural cells. Macrophage, a type of immune system cells, plays critical roles in various diseases, including cancer, atherosclerosis, rheumatoid arthritis, infection and inflammation, due to the recognition and engulfment function of removing substances and pathogens. Macrophage membranes inherit the surface protein profiles and biointerfacing properties of source cells. Therefore, the macrophage membrane cloaking can protect synthetic nanoparticles from phagocytosis by the immune cells. Meanwhile, the macrophage membrane can make use of the natural correspondence to accurately recognize antigens and target inflamed tissue or tumor sites. In this review, we have summarized the advances in the fabrication, characterization and homing capacity of macrophage membrane cloaking nanoparticles in various diseases, including cancers, immune diseases, cardiovascular diseases, central nervous system diseases, and microbial infections. Although macrophage membrane-camouflaged nanoparticles are currently in the fetal stage of development, there is huge potential and challenge to explore the conversion mode in the clinic.

References 173

1. 1.

   Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655-672.

   Not in our library10.1038/nrd4363

2. 2.

   Pombo García K, Zarschler K, Barbaro L, Barreto JA, O'Malley W, Spiccia L, et al. Zwitterionic-coated “stealth” nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. Small. 2014;10(13):2516-2529.

   Not in our library10.1002/smll.201303540

3. 3.

   Batty CJ, Bachelder EM, Ainslie KM. Historical perspective of clinical nano and microparticle formulations for delivery of therapeutics. Trends Mol Med. 2021;27(6):516-519.

   Not in our library10.1016/j.molmed.2021.04.002

4. 4.

   Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater. 2003;5:1-16.

   Not in our library10.22203/ecm.v005a01

5. 5.

   Song G, Petschauer JS, Madden AJ, Zamboni WC. Nanoparticles and the mononuclear phagocyte system: pharmacokinetics and applications for inflammatory diseases. Curr Rheumatol Rev. 2014;10(1):22-34.

   Not in our library10.2174/1573403x10666140914160554

6. 6.

   Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG—a versatile conjugating ligand for drugs and drug delivery systems. J Control Release. 2014;192:67-81.

   Not in our library10.1016/j.jconrel.2014.06.046

7. 7.

   Wang Y, Wang C, Fu S, Liu Q, Dou D, Lv H, et al. Preparation of Tacrolimus loaded micelles based on poly(Ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone). Int J Pharm. 2011;407(1–2):184-189.

   Not in our library10.1016/j.ijpharm.2011.01.018

8. 8.

   Hu CM, Fang RH, Wang KC, Luk BT, Thamphiwatana S, Dehaini D, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526(7571):118-121.

   Not in our library10.1038/nature15373

9. 9.

   Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, Yousefi M, et al. Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett. 2017;190:64-83.

   Not in our library10.1016/j.imlet.2017.07.015

10. 10.

    Vandghanooni S, Eskandani M, Barar J, Omidi Y. As1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells. Nanomedicine. 2018;13(21):2729-2758.

    Not in our library10.2217/nnm-2018-0205

11. 11.

    Ding D, Tang X, Cao X, Wu J, Yuan A, Qiao Q, et al. Novel self-assembly endows human serum albumin nanoparticles with an enhanced antitumor efficacy. AAPS PharmSciTech. 2014;15(1):213-222.

    Not in our library10.1208/s12249-013-0041-3

12. 12.
    Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery · 2019

    Corrected
13. 13.

    Xia Q, Zhang Y, Li Z, Hou X, Feng N. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B. 2019;9(4):675-689.

    Not in our library10.1016/j.apsb.2019.01.011

14. 14.

    Xuan M, Shao J, Dai L, He Q, Li J. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv Healthcare Mater. 2015;4(11):1645-1652.

    Not in our library10.1002/adhm.201500129

15. 15.

    Liu G, Zhao X, Zhang Y, Xu J, Xu J, Li Y, et al. Engineering biomimetic platesomes for pH-responsive drug delivery and enhanced antitumor activity. Adv Mater. 2019;31(32):e1900795.

    Not in our library10.1002/adma.201900795

16. 16.

    Toledano Furman NE, Lupu-Haber Y, Bronshtein T, Kaneti L, Letko N, Weinstein E, et al. Reconstructed stem cell nanoghosts: a natural tumor targeting platform. Nano Lett. 2013;13(7):3248-3255.

    Not in our library10.1021/nl401376w

17. 17.

    Li J, Zhen X, Lyu Y, Jiang Y, Huang J, Pu K. Cell membrane coated semiconducting polymer nanoparticles for enhanced multimodal cancer phototheranostics. ACS Nano. 2018;12(8):8520-8530.

    Not in our library10.1021/acsnano.8b04066

18. 18.

    Kunde SS, Wairkar S. Platelet membrane camouflaged nanoparticles: biomimetic architecture for targeted therapy. Int J Pharm. 2021;598:120395.

    Not in our library10.1016/j.ijpharm.2021.120395

19. 19.
    Cancer Cell Membrane-Coated Nanoparticles for Cancer Management · 2019

    No notice
20. 20.

    Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harbor Perspect Biol. 2012;4(3):19.

    Not in our library10.1101/cshperspect.a006049

21. 21.

    Gomez Perdiguero ESC, Geissmann F. Development and homeostasis of resident myeloid cells the case of the microglia. Glia. 2013 Jan; 112-120.

    Not in our library10.1002/glia.22393

22. 22.

    Wynn TA, Chawla A, Pollard JW. Macrophage biology in development homeostasis and disease. Nature. 2013;496(7446):445-455.

    Not in our library10.1038/nature12034

23. 23.

    Epelman S, Lavine Kory J, Randolph GJ. Origin and functions of tissue macrophages. Immunity. 2014;41(1):21-35.

    Not in our library10.1016/j.immuni.2014.06.013

24. 24.

    Lemke G. How macrophages deal with death. Nat Immunol. 2019;19(9):539-549.

    Not in our library10.1038/s41577-019-0167-y

25. 25.

    Tom Cotter AMd, Henson Peter M. The final step in programmed cell death phagocytes carry apoptotic cells to the grave. Biochem. 2003;39:105-117.

    Not in our library10.1042/bse0390105

26. 26.

    Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593-604.

    Not in our library10.1016/j.immuni.2010.05.007

27. 27.

    Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-896.

    Not in our library10.1038/ni.1937

28. 28.

    Chen Y, Zhang X. Pivotal regulators of tissue homeostasis and cancer: macrophages. Exp Hematol Oncol. 2017;6:23.

    Not in our library10.1186/s40164-017-0083-4

29. 29.

    Andón FT, Digifico E, Maeda A, Erreni M, Mantovani A, Alonso MJ, et al. Targeting tumor associated macrophages: the new challenge for nanomedicine. Semin Immunol. 2017;34:103-113.

    Not in our library10.1016/j.smim.2017.09.004

30. 30.

    Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, et al. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008;205(6):1261-1268.

    Not in our library10.1084/jem.20080108

31. 31.

    Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal os that spur autophagy and immunity. Immunol Rev. 2012;249(1):158-175.

    Not in our library10.1111/j.1600-065x.2012.01146.x

32. 32.

    Zindel J, Kubes P. DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation. Annu Rev Pathol. 2020;15:493-518.

    Not in our library10.1146/annurev-pathmechdis-012419-032847

33. 33.

    Poudel K, Banstola A, Gautam M, Soe Z, Phung CD, Pham LM, et al. Macrophage-membrane-camouflaged disintegrable and excretable nanoconstruct for deep tumor penetration. ACS Appl Mater Interfaces. 2020;12(51):56767-56781.

    Not in our library10.1021/acsami.0c17235

34. 34.

    Si J, Shao S, Shen Y, Wang K. Macrophages as active nanocarriers for targeted early and adjuvant cancer chemotherapy. Small. 2016;12(37):5108-5119.

    Not in our library10.1002/smll.201601282

35. 35.

    Cao H, Dan Z, He X, Zhang Z, Yu H, Yin Q, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano. 2016;10(8):7738-7748.

    Not in our library10.1021/acsnano.6b03148

36. 36.

    Li B, Wang W, Song W, Zhao Z, Tan Q, Zhao Z, et al. Antiviral and anti-inflammatory treatment with multifunctional alveolar macrophage-like nanoparticles in a surrogate mouse model of COVID-19. Adv Sci. 2021;8(13):2003556.

    Not in our library10.1002/advs.202003556

37. 37.
    Cell Membrane-Camouflaged Nanoparticles: A Promising Biomimetic Strategy for Cancer Theragnostics · 2018

    No notice
38. 38.

    Rao L, Zhao SK, Wen C, Tian R, Lin L, Cai B, Sun Y, Kang F, Yang Z, He L, Mu J, Meng QF, Yao G, Xie N, Chen X. Activating macrophage-mediated cancer immunotherapy by genetically edited nanoparticles. Adv Mater. 2020;32:47.

    Not in our library10.1002/adma.202004853

39. 39.
    Amelioration of ulcerative colitis via inflammatory regulation by macrophage-biomimetic nanomedicine · 2020

    No notice
40. 40.
    Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy · 2020

    No notice

Cited by papers we hold 2

• Macrophage-mimetic liposomes co-delivering ceria and Ac2-26 peptide for penumbra protection in ischemic stroke · 2025
  Not checked
• Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets · 2025
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.